Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Currently Reading
Dr Sara M. Tolaney on Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast Cancer
August 08, 2018
Dr Dennis P. Scanlon Explains Costs Associated With the Opioid Epidemic
July 27, 2018
Dr Michael Thompson Outlines Challenges With the Mass Adoption of EHRs, Precision Medicine
July 25, 2018
Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer
July 23, 2018
Dr Peter Paul Yu Explains Current Challenges With Precision Medicine
July 18, 2018
Where Dr Victoria Villaflor Thinks the Future of Precision Medicine Is Headed
July 08, 2018
Dr Peter Paul Yu on Progress in the Move Toward Interoperability
July 06, 2018
Dr Michael Thompson on Conducting Precision Medicine Trials in the Community Setting
July 05, 2018
Leonard Saltz: Novel Approaches to Colon Cancer, Behaviors That Impact Survival
July 02, 2018
Dr Sara M. Tolaney: Standard of Care, Novel Approaches for Treatment of HER2-Positive Breast Cancer
June 28, 2018
Dr Victoria Villaflor Discusses How Novel Therapies Have Changed Cancer Treatment
June 26, 2018
Dr Peter Paul Yu: How Next-Generation Sequencing is Changing Cancer Care
June 21, 2018
Dr James Lin Chen on the Shift to Precision Medicine
June 18, 2018
Ellen Miller Sonet: The Importance of Cancer Care Providers Informing Patients of Treatment Costs
June 17, 2018
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16, 2018
Dr Leonard B. Saltz: The Role of Next-Generation Sequencing in Advancing Precision Medicine
June 14, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018

Nelarabine With Chemotherapy Boosted Outcomes in Pediatric and YA Patients With T-Cell Cancers

Surabhi Dangi-Garimella, PhD
A phase 3 study, conducted by the Children’s Oncology Group among children and young adults between ages 1 and 30 diagnosed with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic leukemia, has found a 90% survival rate at 4 years posttreatment initiation—84% of these patients were declared cancer free at that point in their treatment trajectory. Results from this study will be presented at the 2018 American Society of Clinical Oncology Annual Meeting, June 1-5, in Chicago, Illinois.
A phase 3 study, conducted by the Children’s Oncology Group (COG) in 2007, among children and young adults between ages 1 and 30 diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LL) has found a 90% survival rate at 4 years posttreatment initiation—84% of these patients were declared cancer free at that point in their treatment trajectory. Results from this study will be presented at the 2018 American Society of Clinical Oncology Annual Meeting, June 1-5, in Chicago, Illinois.

The COG AALL0434 study enrolled 1895 patients during an 8-year period (January 2007- July 2014) to test nelarabine, an antineoplastic agent directed against T cells, in combination with chemotherapy. The trial had 4 arms; all patients received COG augmented Berlin-Frankfurt-Munster or aBFM chemotherapy. Additionally, they were randomized to receive escalating dose methotrexate without leucovorin rescue + pegaspargase (CMTX) or high-dose methotrexate (HDMTX) + leucovorin rescue. Patients with moderate and high risk were randomized to receive, or not receive, six 5-day courses of nelarabine 650 mg/m2/day, complemented with chemotherapy and cranial radiation.

“T-cell ALL is a disease that requires the use of a very intense and complex chemotherapy regimen. Historically, about 80% of people live at least four years after being treated for their disease, but we felt we could and must do better,” lead author Kimberly Dunsmore, MD, professor, Virginia Tech Carilion School of Medicine in Roanoke, said in a press release. “Our trial shows that we could further increase survival rates by about 10%, which is very encouraging.”

For all patients, the overall disease-free survival (DFS) rate was 84.3 +/- 1.1% at 4 years, and overall survival (OS) rate was 90.2 +/- 0.9%. The 4-year DFS rate for T-ALL patients randomized to nelarabine (n = 323) versus no nelarabine (n = 336) was 88.9 +/- 2.2% vs 83.3 +/- 2.5%, (P = .0332).

Among T-ALL patients randomized to CMTX, the 4-year DFS for nelarabine (n = 147) versus no nelarabine (n = 151) was 92.2 +/- 2.8% vs 89.8 +/- 3.0% (P = .3825). For patients randomized to HDMTX, the 4-year DFS was 86.2 +/- 3.2% with nelarabine (n = 176) vs 78.0 +/- 3.7% without nelarabine (n = 185; P = 0.024).

Importantly, there was no advantage of nelarabine treatment for high risk T-LL patients; 4-year DFS was 85.0 +/- 5.6% for nelarabine (n = 60) and it was 89.0 +/- 4.7% for patients who did not receive nelarabine (n = 58; P = .2788).

Overall toxicity and neurotoxicity were acceptable and not significantly different between all 4 arms, the authors concluded.

Future studies are directed to evaluate using nelarabine along with chemotherapy without cranial radiation, to avoid the late side effects associated with radiating the brain, including cognitive changes, learning disabilities, neuroendocrine changes and the development of secondary cancers.

Reference

Dunsmore KP, Winter S, Devidas M, et al. COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy. J Clin Oncol. 2018;36,(suppl; abstr 10500).

Related Articles

Integrating Genomics into Pediatric Cancer Care
NCHS Report: Rising Survivorship in Pediatric Cancers, Brain Cancer Leading Cause of Death
Persephone Trial: Cutting Trastuzumab Duration by Half Safer, Efficacious in HER2-Positive Breast Cancer
Dr Peter Paul Yu Discusses the Impact of Health Information Technology in Oncology
Identifying Rational Immunotherapy Combinations for Glioblastoma: A Progress Report
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!